pharmaphorum

MARCH 22, 2024

First report from PHTI concludes that digital health technologies for diabetes management deliver minimal clinical benefit and raise healthcare costs

Healthcare 105

Healthcare Healthcare Management 105

World of DTC Marketing

MARCH 29, 2022

Healthy eating is your recipe for managing diabetes. More than 37 million Americans have diabetes (about 1 in 10), and approximately 90-95% have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more children, teens, and young adults are also developing it.

Insurance 231

Insurance Education Healthcare Healthcare 231

Fierce Pharma

JUNE 27, 2023

Diabetes patients in the United Kingdom may have to wait a bit longer to get their hands on Eli Lilly’s Mounjaro after the country’s drug value watchdog kiboshed its coverage recommendation.

Patients 198

Patients 198

European Pharmaceutical Review

DECEMBER 7, 2023

Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. 

Management 105

Management Medical Medicine Leads 105

European Pharmaceutical Review

MARCH 8, 2024

Study design The randomised, double-blind, parallel-group clinical trial compared injectable semaglutide 1.0mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular.

Manufacturing 94

Manufacturing Pharmaceutical 94

European Pharmaceutical Review

OCTOBER 18, 2023

TZIELD (teplizumab-mzwv) has demonstrated TZIELD’s potential to slow disease progression in newly diagnosed children and adolescents with Stage 3 type 1 diabetes. Data from the Phase III PROTECT clinical trial , presented at the 2023 Annual ISPAD Conference, showed that superior beta cell preservation was observed compared to placebo.

Medicine 108

Medicine Safety Patients Medical 108

MedCity News

NOVEMBER 10, 2022

Sprinter Health is integrating its at-home clinical and diagnostic services into Firefly Health’s virtual primary care model. Firefly’s members will be able to receive common medical services from Sprinter clinicians in their homes — such as vital checks, blood draws, electrocardiograms, diabetic eye exams and diabetic foot screenings.

Medical 138

Medical Healthcare Healthcare 138

MedCity News

FEBRUARY 3, 2023

Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.

Medicine 114

Medicine Leads Marketing Biopharma 114

European Pharmaceutical Review

DECEMBER 5, 2023

billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes.

Food 95

Food Leads Pharma Patients 95

World of DTC Marketing

AUGUST 13, 2021

SUMMARY: Treating Americans with diabetes now costs more than the U.S. 85 percent of people with diabetes are overweight. While not all diabetes cases are linked to weight gain, overeating and eating too much is still the main cause of type 2 diabetes. Reuters this morning had a story on diabetes that scared me a lot.

Insurance 187

Insurance Medical Patients Management 187

World of DTC Marketing

JUNE 27, 2021

mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight” In the clinical study, participants were enrolled in an “intensive” behavioral study with 8 weeks low-calorie diet. We are an obese country, and diabetes is getting worse.

Side effects 194

Side effects Patients Insurance Doctors 194

World of DTC Marketing

MAY 16, 2022

Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes. The drug led to impressive blood sugar and body weight drops in clinical trials. The approval for tirzepatide—which Lilly will market under the brand name Mounjaro—isn’t for weight loss but Type 2 diabetes.

Food and Drug Administration 218

Food and Drug Administration Side effects Pharma Prescription 218

European Pharmaceutical Review

SEPTEMBER 8, 2023

Eli Lilly ’s Mounjaro (tirzepatide), has been recommended to treat poorly controlled type 2 diabetes in adults alongside diet and exercise. Compared with semaglutide , insulin therapy or a placebo, tirzepatide demonstrated that 81 percent to 97 percent of people achieved better glucose control in clinical trials.

Food and Drug Administration 98

Food and Drug Administration Medicine Food Manufacturing 98

European Pharmaceutical Review

OCTOBER 31, 2023

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to results of the year-long ONWARDS 6 Phase IIIa clinical trial, recently published in the Lancet. Funding was provided by Novo Nordisk.

Management 97

Management Consulting Safety Pharmaceutical 97

PharmExec

APRIL 7, 2023

Eli Lilly debuts its first Mounjaro TV commercial amid high demand for the diabetes injection, which also shows promise in weight loss applications and outperformed rivals Ozempic and Wegovy in clinical trials.

119

119

Pharmacy Times

DECEMBER 5, 2022

Teplizumab is a humanized IgG1? Fc-nonbinding anti-CD3 monoclonal antibody that blocks T cells, preventing them from attacking beta cells.

49

49

European Pharmaceutical Review

NOVEMBER 18, 2022

Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA). The drug binds to certain immune system cells and delays progression to stage 3 type 1 diabetes.

Food and Drug Administration 95

Food and Drug Administration FDA Side effects Food 95

European Pharmaceutical Review

JUNE 27, 2023

Lonza and Vertex Pharmaceuticals Incorporated have agreed to collaborate to support the manufacture of Vertex’s Type 1 diabetes cell therapy portfolio. To support diabetes cell therapy production, construction of the US manufacturing facility is scheduled to begin later this year.

Manufacturing 95

Manufacturing Pharmaceutical Patients 95

Pharmacy Times

JULY 20, 2023

Despite the surge in new diabetes cases, the treatment options in in children remain limited.

Medical 37

Medical 37

Pharmacy Times

OCTOBER 25, 2022

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease.

Patients 49

Patients Management 49

Pharmaceutical Technology

JANUARY 4, 2024

Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Diabetic Macular Edema.

75

75

MedCity News

APRIL 28, 2023

Merck, Sanofi, and Eli Lilly joined the Series A financing of Therini Bio, a startup developing a drug that selectively targets fibrin as a way of reducing disease-driving inflammation in neurodegeneration and eye disorders such as diabetic macular edema. Therini is preparing to advance its lead program to clinical testing.

Leads 111

Leads Biopharma Pharma 111

Pharmaceutical Technology

OCTOBER 7, 2022

Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.

Food and Drug Administration 119

Food and Drug Administration FDA Healthcare Provider Prospecting 119

MedCity News

OCTOBER 17, 2022

Research shows that the company’s AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.

133

133

Pharmaceutical Technology

JUNE 7, 2023

The application was filed for the treatment of diabetic nephropathy/diabetic kidney disease. Glomerular diseases include focal segmental glomerulosclerosis, Alport syndrome and diabetic kidney disease. VAR 200 works by removing the extra lipids from the kidney. There are no therapeutic options available that address this issue.

Transportation 98

Transportation Leads Patients 98

European Pharmaceutical Review

DECEMBER 7, 2022

percent when used alongside other baseline treatments (diet, exercise, metformin and/or insulin), compared with placebo in a Phase III clinical trial of children and adolescents aged 10-17 years with type 2 diabetes. What is your opinion on Jardiance ® (empagliflozin) becoming another option for managing type 2 diabetes?

Safety 87

Safety Management Medicine Medical 87

Pharmaceutical Technology

NOVEMBER 17, 2023

CH-0601 is under clinical development by Caelus Health and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes).

52

52

European Pharmaceutical Review

AUGUST 14, 2023

Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics – and their lead assets focused on obesity and diabetes. Lilly announced the successful completion of its acquisition of clinical-stage Versanis Bio and its lead asset bimagrumab, an anti-obesity medicine.

Biopharma 90

Biopharma Leads Medicine Management 90

European Pharmaceutical Review

DECEMBER 8, 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over. The average percentage change in weight over the trial period was -16.0 percent for the 5mg dose, -21.4 percent for the 10mg dose, -22.5

Management 88

Management Medicine Food Healthcare 88

Pharmaceutical Technology

APRIL 12, 2023

Clinical-stage biotechnology firm LyGenesis has formed a joint research collaboration with Imagine Pharma to develop new cell therapies for type 1 diabetes (T1D). In June 2022, the company discovered T1D AIPCs, a critical component to treat T1D through autologous cell transplantation.

Pharma 98

Pharma Leads Patients Pharmaceutical 98

European Pharmaceutical Review

JULY 26, 2023

The oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor is the first type 2 diabetes medicine to include cardiovascular death risk reduction data for patients with type 2 diabetes and cardiovascular disease in its label in several countries.

Medicine 93

Medicine Pharma Patients Medical 93

World of DTC Marketing

JUNE 29, 2022

Clinics offering debunked cancer treatments are still advertising on Facebook despite the company’s efforts to control medical misinformation. Recently there was a vibrant discussion about using supplements to control blood sugar in a diabetes group. Pharma, for the most part, has been dabbling in social media.

Media 228

Media Patients Pharma Medical 228

pharmaphorum

OCTOBER 4, 2022

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app. Diabetes is one of the most prevalent health conditions in the US, affecting over 11% of the population.

Safety 59

Safety Competition Patients 59

European Pharmaceutical Review

MARCH 14, 2024

Additionally, there have been notable clinical developments for the treatment of kidney disorders. This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Internet] Vera Therapeutics. cited 2024Mar].

Food and Drug Administration 95

Food and Drug Administration Side effects Leads Patients 95

LEVO Health

FEBRUARY 1, 2024

Patient Example In a diabetes medication campaign targeting patients based on their treatment history, lifestyle factors, and digital behavior, the campaign could segment audiences into subgroups such as newly diagnosed patients, long-term patients, and those at risk of diabetes.

Healthcare 52

Healthcare Healthcare Patients Marketing 52

European Pharmaceutical Review

MARCH 14, 2024

Additionally, there have been notable clinical developments for the treatment of kidney disorders. This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Internet] Vera Therapeutics. cited 2024Mar].

Food and Drug Administration 94

Food and Drug Administration Side effects Leads Patients 94

Pharmacy Times

JANUARY 3, 2024

Liraglutide, a glucagon-like peptide 1 receptor agonist, has shown a clinically and significant reduction in glycated hemoglobin for those with type 2 diabetes.

59

59